Business Wire

PHILIP-MORRIS

23.3.2020 14:29:10 CET | Business Wire | Press release

Share
Philip Morris International Inc. Announces Temporary Suspension of Operations at Manufacturing Technology Bologna

Philip Morris International Inc. (“PMI”) (NYSE: PM) announced today that it will implement a temporary suspension of its operations at Philip Morris Manufacturing & Technology Bologna S.p.A., Italy (“MTB”) due to the ongoing situation regarding COVID-19. In agreement with social partners, the Company has decided to suspend production for a period of one week, out of an abundance of caution and to support the government’s efforts to limit propagation of COVID-19.

The Company will monitor the situation closely with a view to restarting operations as soon as possible, subject to government requirements.

Although several governments have mandated production facilities to temporarily suspend their operations, currently for periods from one to two weeks, PMI does not currently expect out-of-stock situations in any major operating income markets and believes consumers still have adequate access to its products.

As part of its ongoing business continuity plans, there are adequate inventories of PMI finished goods, on average across all markets, of over two months for heated tobacco units (“HTUs”), over three months for tobacco heating devices, and over one and a half months for cigarettes, based on sales trends recorded prior to the situation generated by the COVID-19 pandemic. Although MTB accounted for approximately 50% of HTU production as of February 2020, PMI’s other HTU facilities currently remain operational, with an annual installed capacity of approximately 70 billion units. The above-mentioned government-mandated production suspensions affect approximately 20% of PMI’s cigarette-production capacity worldwide.

“In this unprecedented global situation, our primary concern remains the health and safety of our colleagues, their families, and the communities in which we operate,” said Jacek Olczak, PMI Chief Operating Officer. “We have therefore decided to temporarily suspend operations at our facility near Bologna. We are committed to doing our part and have taken a number of steps over the last two months to protect our people and ensure continuity of supply to our customers and consumers.”

PMI has implemented a number of measures to protect employees in its manufacturing facilities and offices around the world, including: asking office-based employees to work from home, limiting business travel, canceling large in-person gatherings and events, restricting access to factories to essential workers, implementing temperature screening where permitted, enhancing cleaning and sanitization protocols, compartmentalizing activities, and enforcing personal protective equipment use, personal hygiene and social distancing.

-ENDS-

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of December 31, 2019, PMI estimates that approximately 9.7 million adult smokers around the world have already stopped smoking and switched to PMI's heat-not-burn product, available for sale in 52 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

Forward-Looking and Cautionary Statements

This release contains forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Important factors that may cause actual results and outcomes to differ materially from those contained in the forward-looking statements included in this release are described in PMI publicly filed reports, including those described under Item 1A. “Risk Factors” in PMI’s annual report on Form 10-K for the year ended December 31, 2019 and also entail risks of further developments regarding COVID-19.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ABB Extends Engagement with Wipro to Deliver and Enhance Global Digital Workplace Services2.9.2026 15:30:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading AI-powered technology services and consulting company, has renewed its long-standing Digital Workplace Services contract with ABB, a global technology leader in electrification and automation. Building on an established relationship spanning multiple years, Wipro will continue delivering end-to-end AI-enabled Digital Workplace Services for ABB's global operations while further enhancing employee experience through advanced automation, AI-powered service capabilities, and workplace modernization initiatives. Powered by Wipro Intelligence™, the unified suite of AI platforms, solutions and transformative offerings, this engagement will modernize ABB’s digital workplace with AI-led, experience-centric capabilities delivered through Wipro’s AI Live Workspace™ and Digital Workplace Services offerings and operationalized through WINGS, Wipro’s AI-powered delivery platform for operations. Through SmartOps, Wipro’s AIOps capability,

Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release

Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati

Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release

The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.

Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release

Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye